» Articles » PMID: 12171842

Adverse Behavioral Effects of Treatment for Acute Exacerbation of Asthma in Children: a Comparison of Two Doses of Oral Steroids

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2002 Aug 13
PMID 12171842
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the relative adverse symptomatic effects and benefits of therapy with oral corticosteroids at doses of 2 mg/kg vs 1 mg/kg daily in children with acute exacerbations of asthma.

Methods: Using a questionnaire that addressed symptoms, we conducted a prospective study of the adverse effects and benefits of therapy with prednisone or prednisolone at two dose levels in 86 children who were 2 to 16 years of age with mild persistent asthma during an acute exacerbation and were unresponsive to therapy with inhaled steroids and beta-adrenergic agents. Parents and physicians were blinded to the dose level. Children were assigned to either of the two doses by random allocation. Behavioral side effects were assessed via a questionnaire administered by a physician. Benefits were measured by the resolution of asthma symptoms (cough, shortness of breath, and wheeze) at the completion of the treatment with oral steroids.

Results: Behavioral side effects, particularly anxiety (p < 0.02) and aggressive behavior (p < 0.002), were twice as common in patients receiving a dose of 2 mg/kg/d. Benefits were comparable in the two groups. The number needed to harm (ie, the number of patients receiving experimental treatment that would lead to one additional person being harmed vs patients receiving standard treatment) was 6.1 for anxiety, 8.6 for hyperactivity, and 4.8 for aggressive behavior.

Conclusions: Because the adverse side effects were greater at the higher dose but the benefits were comparable, we recommend using an oral corticosteroid dose of 1 mg/kg daily for children with mild persistent asthma who present with an acute exacerbation of asthma.

Citing Articles

GEMA 5.3. Spanish Guideline on the Management of Asthma.

Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G Open Respir Arch. 2023; 5(4):100277.

PMID: 37886027 PMC: 10598226. DOI: 10.1016/j.opresp.2023.100277.


Characteristics of medicine use for children with asthma in China: a nationwide population-based study.

Wu P, Xu B, Shen A, Zeng H, Shen K BMC Pediatr. 2022; 22(1):740.

PMID: 36578005 PMC: 9795755. DOI: 10.1186/s12887-022-03720-5.


Chronic pediatric diseases and risk for reading difficulties: a narrative review with recommendations.

Perazzo D, Moore R, Kasparian N, Rodts M, Horowitz-Kraus T, Crosby L Pediatr Res. 2022; 92(4):966-978.

PMID: 35121848 PMC: 9586865. DOI: 10.1038/s41390-022-01934-y.


A 3-day course of 1 mg/kg versus 2 mg/kg bodyweight prednisolone for 1- to 5-year-old children with acute moderate exacerbation of asthma: a randomized double-blind noninferiority trial.

Buddala P, Chandrasekaran V, Harichandrakumar K Paediatr Child Health. 2021; 26(4):e189-e193.

PMID: 34136056 PMC: 8194769. DOI: 10.1093/pch/pxaa082.


How can we minimise the use of regular oral corticosteroids in asthma?.

Bourdin A, Adcock I, Berger P, Bonniaud P, Chanson P, Chenivesse C Eur Respir Rev. 2020; 29(155).

PMID: 32024721 PMC: 9488989. DOI: 10.1183/16000617.0085-2019.